Leerink Partnrs Issues Positive Outlook for BBIO Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Investment analysts at Leerink Partnrs upped their Q2 2025 earnings per share estimates for shares of BridgeBio Pharma in a research note issued on Tuesday, July 15th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($0.69) for the quarter, up from their previous estimate of ($0.71). The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma's Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($2.72) EPS, FY2026 earnings at ($1.58) EPS, FY2027 earnings at $0.32 EPS and FY2028 earnings at $3.15 EPS.

Other analysts also recently issued reports about the company. Redburn Atlantic began coverage on BridgeBio Pharma in a research note on Monday, March 31st. They set a "buy" rating and a $50.00 target price on the stock. Wall Street Zen raised BridgeBio Pharma from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Wolfe Research started coverage on BridgeBio Pharma in a report on Tuesday, June 17th. They issued an "outperform" rating and a $49.00 target price on the stock. Citigroup raised their price target on BridgeBio Pharma from $58.00 to $67.00 and gave the company a "buy" rating in a report on Friday, July 11th. Finally, Bank of America lifted their target price on BridgeBio Pharma from $50.00 to $54.00 and gave the stock a "buy" rating in a report on Wednesday, June 25th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $61.20.

BridgeBio Pharma Price Performance

BBIO stock traded down $0.23 on Thursday, reaching $46.51. 2,139,105 shares of the company traded hands, compared to its average volume of 2,547,424. BridgeBio Pharma has a one year low of $21.72 and a one year high of $48.68. The company has a market cap of $8.83 billion, a P/E ratio of -13.18 and a beta of 1.15. The firm has a fifty day simple moving average of $39.54 and a 200-day simple moving average of $35.78.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.12. The firm had revenue of $36.74 million during the quarter, compared to the consensus estimate of $57.14 million. During the same period in the prior year, the company posted ($0.20) EPS. The firm's revenue was down 44.8% on a year-over-year basis.

Institutional Trading of BridgeBio Pharma

A number of hedge funds have recently bought and sold shares of the stock. Farallon Capital Management LLC lifted its holdings in shares of BridgeBio Pharma by 140.1% during the 4th quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company's stock valued at $115,111,000 after purchasing an additional 2,448,000 shares during the last quarter. Driehaus Capital Management LLC purchased a new stake in shares of BridgeBio Pharma during the 1st quarter valued at $51,874,000. Invesco Ltd. lifted its holdings in shares of BridgeBio Pharma by 147.0% during the 1st quarter. Invesco Ltd. now owns 2,206,163 shares of the company's stock valued at $76,267,000 after purchasing an additional 1,313,036 shares during the last quarter. Woodline Partners LP increased its position in shares of BridgeBio Pharma by 132.9% in the 4th quarter. Woodline Partners LP now owns 2,211,521 shares of the company's stock valued at $60,684,000 after acquiring an additional 1,261,772 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in shares of BridgeBio Pharma by 4,544.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,120,933 shares of the company's stock valued at $38,751,000 after acquiring an additional 1,096,799 shares during the period. Hedge funds and other institutional investors own 99.85% of the company's stock.

Insider Transactions at BridgeBio Pharma

In related news, Director Frank Mccormick sold 100,000 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $44.23, for a total value of $4,423,000.00. Following the completion of the sale, the director owned 879,979 shares in the company, valued at approximately $38,921,471.17. The trade was a 10.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Global Investors Lp Viking sold 3,500,000 shares of the company's stock in a transaction on Friday, June 27th. The stock was sold at an average price of $44.00, for a total value of $154,000,000.00. Following the sale, the insider owned 18,555,375 shares of the company's stock, valued at approximately $816,436,500. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 9,926,181 shares of company stock valued at $375,528,164 in the last ninety days. Corporate insiders own 18.20% of the company's stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.